ReNeuron Group (RENE) Share Price, News & Analysis

Company Overview

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 177,373 shs
• Average Volume: 578,249 shs
• Market Capitalization: £1.93 million
• P/E Ratio: N/A
• Dividend Yield: 0.76%
• Price Target: N/A
• Consensus Rating: N/A

RENE Stock Analysis - Frequently Asked Questions

How were ReNeuron Group's earnings last quarter?

ReNeuron Group plc (LON:RENE) released its earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, topping analysts' consensus estimates of ($50.20) by $14.30.

How do I buy shares of ReNeuron Group?

Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR) and Sirius Minerals (SXX).

Company Calendar

• Last Earnings: 7/20/2020
• Today: 8/29/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Trading
• Current Symbol: LON:RENE
• CIK: N/A
• Web: www.reneuron.com
• Phone: +44-20-38198400
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£5.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -106.77%
• Return on Assets: -37.91%

Debt

• Debt-to-Equity Ratio: 14.25
• Current Ratio: 1.51
• Quick Ratio: 2.02

Sales & Book Value

• Annual Sales: £783 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.61
• Book Value: GBX 4 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 57,170,000
• Free Float: N/A
• Market Cap: £1.93 million
• Optionable: Not Optionable
• Beta: 0.83